ERBB2 and breast carcinoma: The PALOMA-2 trial, a randomized double-blind phase III study, evaluated palbociclib plus letrozole versus letrozole alone in 666 postmenopausal women with treatment-naïve, unresectable, locally advanced or metastatic HR+/HER2- breast cancer.